Your browser doesn't support javascript.
loading
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection.
Jamieson, Taylor R; Poutou, Joanna; Marius, Ricardo; He, Xiaohong; Rezaei, Reza; Azad, Taha; Ilkow, Carolina S.
  • Jamieson TR; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa.
  • Poutou J; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa.
  • Marius R; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa.
  • He X; Ottawa Hospital Research Institute.
  • Rezaei R; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa.
  • Azad T; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa.
  • Ilkow CS; Ottawa Hospital Research Institute; Department of Biochemistry, Microbiology and Immunology, University of Ottawa; cilkow@ohri.ca.
J Vis Exp ; (172)2021 06 05.
Article en En | MEDLINE | ID: mdl-34152313
ABSTRACT
As the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, it has become evident that the presence of neutralizing antibodies against the virus may provide protection against future infection. Thus, as the creation and translation of effective COVID-19 vaccines continues at an unprecedented speed, the development of fast and effective methods to measure neutralizing antibodies against SARS-CoV-2 will become increasingly important to determine long-term protection against infection for both previously infected and immunized individuals. This paper describes a high-throughput protocol using vesicular stomatitis virus (VSV) pseudotyped with the SARS-CoV-2 spike protein to measure the presence of neutralizing antibodies in convalescent serum from patients who have recently recovered from COVID-19. The use of a replicating pseudotyped virus eliminates the necessity for a containment level 3 facility required for SARS-CoV-2 handling, making this protocol accessible to virtually any containment level 2 lab. The use of a 96-well format allows for many samples to be run at the same time with a short turnaround time of 24 h.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Imagen Óptica / Glicoproteína de la Espiga del Coronavirus / Prueba Serológica para COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Imagen Óptica / Glicoproteína de la Espiga del Coronavirus / Prueba Serológica para COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article